Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · solution, preloaded autoinjector pen

Epic Peptides Lab · USA

Document number: PL-SDS-088
Revision: 1.0 · 2026-10-03

IGF-1 LR3

solution, preloaded autoinjector pen

1Identification

Product Identifier

IGF-1 LR3

Document Number

PL-SDS-088

Catalogue Items Covered

Id
14104
Name
Preloaded Autoinjector | IGF1 LR3 | 3ml Pen | 1mg/ml
Sku
PL-IGF1LR3-3ML-PEN

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification: Not classified as hazardous under OSHA HCS 2012 (29 CFR 1910.1200) or UN GHS, on the basis of the supplier safety data sheets consulted.
Label Elements: No data available.
Signal Word: No data available.
Other Hazards: No data available.

3Composition / information on ingredients

Description

Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle.

Composition

Name
IGF-1 LR3
Full
Long R3 IGF-1; recombinant human IGF-1 analogue with a 13-residue N-terminal extension and Glu3→Arg
Cas
143045-27-6
Formula
C400H625N111O115S9 (reduced-chain calculation)
Conc
0.1% w/v
Qty
3 mg per 3 mL pen
Name
Benzyl alcohol (preservative)
Full
Benzyl alcohol, antimicrobial preservative (0.9% w/v in bacteriostatic water)
Cas
100-51-6
Formula
C7H8O
Conc
0.9% w/v
Hazards
- Acute toxicity, oral — Category 4 — H302
- Acute toxicity, inhalation — Category 4 — H332
- Serious eye damage/eye irritation — Category 2A — H319
- Skin sensitisation — Category 1B — H317
Name
Water for injection
Full
Water for injection
Cas
7732-18-5
Formula
H2O
Conc
balance to 100%

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
Injection: For an accidental needle-stick: wash the site with soap and water, do not squeeze, cover with a dressing and seek medical advice; report the incident according to your laboratory's sharps procedure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Accidental needle-stick injection; skin and eye contact from splashes; ingestion is unlikely.

5Fire-fighting measures

Fire Fighting Information: Aqueous solution containing 0.9% benzyl alcohol; not flammable and does not support combustion.

6Accidental release measures

Spill And Clean Up Procedures: Absorb small spills with paper towel or an inert absorbent, place in a sealed container for disposal and clean the area with water and detergent. Pick up broken glass with tongs or forceps, never by hand.

7Handling and storage

Safe Handling: Handle the device as a sharp: never recap or reuse needles, keep fingers away from the needle, and discard used devices into a rigid sharps container. Avoid splashes to eyes and skin. Wash hands after handling.
Safe Storage: Store at 2–8 °C in the original carton, protected from light. Do not freeze; discard if the solution has frozen or is discoloured or cloudy. Once in use, keep the device capped between uses.
Storage Temperature: 2–8 °C, protected from light; do not freeze
Incompatible Materials: No known; proteases

8Exposure controls / personal protection

Occupational Exposure Limits: Benzyl alcohol: no OSHA PEL, ACGIH TLV or NIOSH REL; AIHA WEEL 10 ppm (44 mg/m³) 8-h TWA. Present at 0.9%.

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Liquid

Appearance

Clear, colourless to faintly yellow aqueous solution

Properties

Odor: Odourless to faint aromatic odour (benzyl alcohol)
Ph: Approximately 4.5–7.0 (bacteriostatic water, USP) unless adjusted
Melting: About 0 °C (aqueous solution)
Boiling: About 100 °C (aqueous solution)
Flash: Not flammable; aqueous solution (benzyl alcohol flash point 93–101 °C, present at 0.9%)
Vapour: As water (about 2.3 kPa at 20 °C)
Density: About 1.00–1.02 g/mL at 20 °C
Solubility: Aqueous solution; miscible with water
Logp: Not applicable (protein)
Decomp: Not applicable (aqueous solution); dissolved peptide degrades on heating

10Stability and reactivity

Stability And Reactivity

Reactivity: Stable under normal conditions of use (Repligen); protein - avoid freeze-thaw, store lyophilizate desiccated below -18 °C
Incompatible: No known (Repligen); strong oxidizers, strong acids/bases, proteases (generic)
Decomposition: No known hazardous decomposition products (Repligen); combustion gives carbon oxides, nitrogen oxides, sulfur oxides
Conditions To Avoid: Heat, repeated freeze-thaw, microbial contamination, vigorous shaking of solutions

Conditions To Avoid

Heat, repeated freeze-thaw, microbial contamination, vigorous shaking of solutions

Incompatible Materials

No known; proteases

11Toxicological information

Toxicological Information: Acute toxicity, oral
No data available

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
May be irritating to skin (Repligen); not classified

Serious eye damage/irritation
May be irritating to eye (Repligen); not classified

Respiratory or skin sensitisation
No known significant effect (Repligen); remark: lyophilized recombinant proteins can act as respiratory sensitisers (H334 consideration for powders)

Germ cell mutagenicity
No known significant effect (Repligen)

Carcinogenicity
No known significant effect (Repligen); not listed by IARC, NTP, OSHA

Reproductive toxicity
No data available

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Accidental needle-stick injection; skin and eye contact from splashes; ingestion is unlikely.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Readily biodegradable; EC50 Daphnia magna > 100 mg/L/48 h (Repligen liquid product).

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Not addressed by supplier; recombinant proteins are generally not TSCA-listed (research use)
Carcinogen Listings: Not listed
Dea: Not a controlled substance
Other: WADA remark: prohibited at all times under S2 (growth factors - IGF-1 and its analogues). Not an approved drug (mecasermin is the approved IGF-1; LR3 is a cell-culture reagent).

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Repligen

Biomol / ProSpec-type datasheet

Sigma-Aldrich

Sigma-Aldrich / Supelco

MilliporeSigma

Sigma-Aldrich BVBA

Aldrich

American Regent - Sterile Water for Injection, USP

Hospira/Pfizer - Bacteriostatic Water for Injection
Confidence: medium
Additional Information: Lyophilised recombinant or purified protein. Inhalation of protein dusts can sensitise susceptible individuals; avoid generating dust and handle the dry powder in a ventilated enclosure. Not classified for respiratory sensitisation because no substance-specific data exist.

Peptide hormone or hormone analogue with potent pharmacological activity at microgram doses. Not classified for reproductive toxicity on the available data, but exposure should be avoided during pregnancy and while nursing as a precaution.

WADA Prohibited List class S2.

Back to SDS list